Expert Perspective Tumor Board

Pankit Vachhani, MD; Edward Pearson, MD, and Maureen Thyne, PA, discuss evidence-based approaches to myeloproliferative neoplasms, highlighting Janus kinase inhibitor selection strategies for myelofibrosis based on patient-specific factors such as cytopenia profiles and splenomegaly severity while addressing polycythemia vera management through strict hematocrit control, molecular monitoring, and emerging therapies including ruxolitinib, interferons, and hepcidin mimetics that offer disease modification beyond symptom control.

Aaron Gerds, MD; Jeanne Palmer, MD; Prithviraj Bose, MD; and Jonathan Abbas, MD, examine the comprehensive management of myelofibrosis, from molecular mechanisms through various disease stages, focusing on risk stratification, treatment sequencing, quality-of-life outcomes, and the integration of emerging therapies into evidence-based clinical practice.

Panelists discuss recent advancements and treatment strategies for metastatic non–-small cell lung cancer (NSCLC) with actionable alterations, focusing on personalized approaches and targeted therapies in a virtual tumor board setting.

Rafael Fonseca, MD​; Binod Dhakal, MD; Doris K. Hansen, MD; and Adriana Rossi, MD, explore evidence-based treatment strategies for newly diagnosed patients, focusing on transplant-ineligible cases, current therapeutic guidelines, and emerging clinical trial data such as the CEPHEUS study comparing daratumumab plus VRd vs VRd alone.

Yi Bin Chen, MD; Corey Cutler, MD; Sami Brake, MD, and Colleen Danielson, NP, explore the multifaceted aspects of chronic graft-versus-host disease (cGVHD), from its impact on patient quality of life and diagnostic criteria to treatment strategies across multiple lines of therapy, including ruxolitinib, belumosudil, and axatilimab, while addressing clinical considerations and safety profiles.

Led by Dr Katy Beckermann, medical experts navigate three clinical cases, the patient journey, and updates from key clinical trial results.

Expert perspectives on the management of myeloproliferative neoplasms (MPNs) from a virtual tumor board discussion. The segments cover treatment approaches, including the use of JAK inhibitors, and key efficacy and safety data from clinical trials that inform treatment selection.

A panel of experts on renal cell carcinoma discuss patient cases and provide clinical insights on clinical trial data, treatment decisions, and the evolving therapeutic landscape.

Expert perspectives on the management of chronic graft-versus-host disease (cGvHD) from virtual tumor board discussions. The segments cover treatment approaches, supportive care strategies, and clinical trial data on agents like ibrutinib, ruxolitinib, and belumosudil for optimizing care in cGvHD. The discussions also evaluate the management of a severe multi-organ cGvHD case, covering diagnosis, emerging therapies, and supportive interventions, featuring insights from Dr. Catherine Lee, Dr. Yi-Bin Chen, and Karolina Faysman, NP.

A panel of expert oncologists reviews 2 clinical cases of HR+ breast cancer, discusses key clinical trial data, and outlines approaches to biomarker testing.

A panel of experts review clinical scenarios and discuss treatment options for patients with chronic graft versus host disease.

Experts present clinical cases of PEComa, discuss approaches to treating patients, and share their perspectives on key clinical trial data that may impact treatment decisions.

Expert panelists review three clinical cases of endometrial cancer and share their perspective on key clinical trial data that may impact treatment decision-making.

A panel of expert genitourinary oncologists present the case of a patient with advanced clear cell renal cell carcinoma and have a comprehensive discussion on clinical trial data and treatment decisions.

Expert panelists provide an overview of ALK+ NSCLC and present patient cases in the context of key clinical trial data to highlight optimal treatment strategies.

Jason Porter, MD, Eric Vail, MD, and Ana Velázquez Mañana, MD, MSc, present two clinical cases of non-small cell lung cancer (NSCLC), discuss targetable genomic alterations and their approaches to biomarker testing for these patients, and touch on how socioeconomic and racial disparities may effect use of testing.

A panel of experts in multiple myeloma reviews key clinical trial data on the treatment of relapsed/refractory multiple myeloma (R/R MM) and discusses the best treatment approaches in the context of recent treatment approvals.

In this panel discussion, experts review clinical cases of metastatic non-small cell lung cancer (mNSCLC), discuss commonly observed targetable genomic alterations, and share their perspectives on key clinical trial data that could impact treatment decision-making.

An expert panel including two hematologist-oncologists and a pathologist center discussion on patient cases to review the optimal identification and management of blastic plasmacytoid dendritic cell neoplasm.

Moshe Orenstein, MD, gives a brief overview of an exciting upcoming Targeted Oncology Virtual Tumor Board series titled "Advances in Frontline Treatment for Advanced Renal Cell Carcinoma."

Expert panelists center discussion on real-world patient cases to review key clinical trial data and approaches to the management of prostate cancer.

Expert panelists center discussion on patient cases to highlight optimal management strategies in patients with hepatocellular carcinoma.

Experts review prostate cancer clinical cases and discuss approaches to treating patients with PSMA targeted therapies.

A panel of expert oncologists review three clinical cases to highlight key clinical trial data and optimal approaches to treating patients with HER2+ breast cancer.

Experts collaborate on 3 patient scenarios to review the current treatment paradigm of graft versus host disease in the context of key clinical trial data.

A panel of breast cancer experts review clinical cases in hormone receptor-positive breast cancer, focusing on the optimal treatment approaches for patients and updates on key clinical trial data.

Experts in gynecologic oncology review clinical cases in ovarian carcinoma, focusing on individualized approaches to the use of PARP inhibition in the first-line maintenance setting and key clinical trials.